In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.
A single dose of nirsevimab significantly reduced the incidence of medically attended respiratory syncytial virus (RSV)-confirmed lower respiratory tract infections (LRTIs) in healthy infants during their first RSV season, according to the MELODY* study presented at IDWeek 2021.
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
The Spike single-nucleotide polymorphism (SNP) assay, a single-reaction multiplex real-time RT-PCR, provides fast, inexpensive, and sensitive detection of specific mutations associated with SARS-CoV-2 variants of concern (VoC), according to data presented at ID Week 2021.
Households, and not schools, are the major route of coronavirus disease 2019 (COVID-19) transmission for those ≤18 years of age, according to across-sectional study of nearly 400 Hong Kong children and youths who contracted COVID-19 in 2020.
Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 inﬂuenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.
A Hong Kong study demonstrates vertical transfer of antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to babies whose mothers have recovered from coronavirus disease 2019 (COVID-19).
An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.
A wearable chest patch device can continuously monitor vital signs in patients with the coronavirus disease 2019 (COVID-19), facilitating the early detection of cardiovascular deterioration, according to a recent study.